Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$37000.0.

  • Artiva Biotherapeutics' Cash from Financing Activities fell 10002.26% to -$37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100000.0, marking a year-over-year change of. This contributed to the annual value of $162.2 million for FY2024, which is 56510.6% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Cash from Financing Activities stood at -$37000.0 for Q3 2025, which was down 10002.26% from -$72000.0 recorded in Q2 2025.
  • Artiva Biotherapeutics' Cash from Financing Activities' 5-year high stood at $163.9 million during Q3 2024, with a 5-year trough of -$72000.0 in Q2 2025.
  • Its 3-year average for Cash from Financing Activities is $26.9 million, with a median of $239000.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in Artiva Biotherapeutics' Cash from Financing Activities was 59938.12% (2024), while the steepest drop was 10311.85% (2024).
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Cash from Financing Activities stood at $962000.0 in 2023, then tumbled by 103.12% to -$30000.0 in 2024, then fell by 23.33% to -$37000.0 in 2025.
  • Its Cash from Financing Activities was -$37000.0 in Q3 2025, compared to -$72000.0 in Q2 2025 and $239000.0 in Q1 2025.